IRTC - INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that iRhythm Technologies Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - IRTC | Benzinga
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of iRhythm Technologies, Inc. (NASDAQ:IRTC) common stock between January 11, 2022 and May 30, 2023, inclusive (the "Class Period"), have until April 8, 2024 to seek appointment as lead plaintiff of the iRhythm class action lawsuit. Captioned Glazing Employers and Glaziers' Union Local #27 Pension and Retirement Fund v. iRhythm Technologies, Inc., No. 24-cv-00706 (N.D. Cal.), the iRhythm class action lawsuit charges iRhythm as well as certain of iRhythm's top current and former executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the iRhythm class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-irhythm-technologies-inc-class-action-lawsuit-irtc.html
You can also contact attorney J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the iRhythm class action lawsuit must be filed with the court no later than April 8, 2024.
CASE ALLEGATIONS: iRhythm is a digital healthcare company that develops and manufactures heart monitoring devices designed to diagnose arrhythmias.
The iRhythm class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) iRhythm failed to comply with the U.S. Food and Drug Administration's ("FDA") marketing regulations and prohibitions against the promotion of products for uncleared and unapproved uses contrary to representations it made to investors; and (ii) iRhythm failed to report adverse events and other missed arrhythmic events to the FDA in violation of the ...